Khan, A., Lim, T. Y., & Sanna-Cherchi, S. (2024). Mendelian Randomization Unveils Drug Targets for IgA Nephropathy. Journal of the American Society of Nephrology, 35(8), 988–991. https://doi.org/10.1681/asn.0000000000000434

Rehnberg, J., Segelmark, M., Ludvigsson, J. F., & Emilsson, L. (2024). Validation of IgA nephropathy diagnosis in the Swedish Renal Registry. BMC Nephrology, 25(1). https://doi.org/10.1186/s12882-024-03512-2

Rivedal, M., Mikkelsen, H., Marti, H.-P., Liu, L., Kiryluk, K., Knoop, T., Bjørneklett, R., Haaskjold, Y. L., Furriol, J., Leh, S., Paunas, F., Bábíčková, J., Scherer, A., Serre, C., Eikrem, O., & Strauss, P. (2024). Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy. Kidney International, 105(4), 717–730. https://doi.org/10.1016/j.kint.2023.12.010

Rajasekaran, A., Larkina, M., Julian, B. A., Canetta, P. A., Roehm, B. A., Khalid, M., Mariani, L. H., & Rizk, D. V. (2023). Optimal Conservative Therapy Use among Adult Cure Glomerulonephropathy Participants with IgA Nephropathy. Kidney360, 4(12), 1763–1769. https://doi.org/10.34067/kid.0000000000000306

Wooden, B., Tarragon, B., Navarro-Torres, M., & Bomback, A. S. (2023). Complement inhibitors for kidney disease. Nephrology Dialysis Transplantation, 38(Supplement_2), ii29–ii39. https://doi.org/10.1093/ndt/gfad079

Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, L. A., Lafayette, R., Maes, B., Małecki, R., Mercer, A., Noronha, I. L., Oh, S. W., … Zizzi, C. F. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. The Lancet, 402(10417), 2077–2090. https://doi.org/10.1016/s0140-6736(23)02302-4

Kiryluk, K., Freedberg, D. E., Radhakrishnan, J., Segall, L., Jacobson, J. S., Mathur, M., Mohan, S., & Neugut, A. I. (2023). Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review. Kidney360, 4(8), 1112–1122. https://doi.org/10.34067/kid.0000000000000165

Kiryluk, K., Sanchez-Rodriguez, E., Zhou, X.-J., Zanoni, F., Liu, L., Mladkova, N., Khan, A., Marasa, M., Zhang, J. Y., Balderes, O., Sanna-Cherchi, S., Bomback, A. S., Canetta, P. A., Appel, G. B., Radhakrishnan, J., Trimarchi, H., Sprangers, B., Cattran, D. C., Reich, H., … Gharavi, A. G. (2023). Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nature Genetics, 55(7), 1091–1105. https://doi.org/10.1038/s41588-023-01422-x

Liu, L., Khan, A., Sanchez-Rodriguez, E., Zanoni, F., Li, Y., Steers, N., Balderes, O., Zhang, J., Krithivasan, P., LeDesma, R. A., Fischman, C., Hebbring, S. J., Harley, J. B., Moncrieffe, H., Kottyan, L. C., Namjou-Khales, B., Walunas, T. L., Knevel, R., Raychaudhuri, S., … Kiryluk, K. (2022). Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-34456-6

Liang, K. V., Ellis, B. K., Stokes, M. B., Smith, R. J., Gu, X., & Gale, D. P. (2022). Hematuria and Proteinuria in a Patient With Recurrent Pulmonary Illnesses: A Quiz. American Journal of Kidney Diseases, 79(6), A13–A15. https://doi.org/10.1053/j.ajkd.2021.10.015

Marumoto, H., Tsuboi, N., D’Agati, V. D., Sasaki, T., Okabayashi, Y., Haruhara, K., Kanzaki, G., Koike, K., Shimizu, A., Kawamura, T., Rule, A. D., Bertram, J. F., & Yokoo, T. (2021). Total Nephron Number and Single-Nephron Parameters in Patients with IgA Nephropathy. Kidney360, 2(5), 828–841. https://doi.org/10.34067/kid.0006972020